REVB
NASDAQRevelation Biosciences Inc.
Price$1.00-0.22 (-18.03%)
2026-03-042026-06-05
News · 26 weeks44-78%
2025-12-142026-06-07
Mix1790d
- Market7(41%)
- SEC Filings7(41%)
- Insider2(12%)
- Other1(6%)
Latest news
25 items- SECRevelation Biosciences Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
- NEWSRevelation Biosciences Expands Acute Kidney Injury Advisory BoardSAN DIEGO, CA / ACCESS Newswire / June 1, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today announced the expansion of its Acute Kidney Injury (AKI) Advisory Board, with the addition of two new members, Dr. Peter Pickkers and Dr. Lui Forni, ahead of its upcoming Phase 2/3 clinical trial. The distinguished panel comprises internationally recognized nephrologists and critical care physicians who will guide the company's clinical strategy, monitor trial progress, and advance Gemini as a treatment for AKI. Drawing on their collective expertise, the boa
- SECSEC Form SCHEDULE 13G filed by Revelation Biosciences Inc.SCHEDULE 13G - REVELATION BIOSCIENCES, INC. (0001810560) (Subject)
- SECSEC Form DEF 14A filed by Revelation Biosciences Inc.DEF 14A - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
- NEWSRevelation Biosciences, Inc. Releases Corporate Update Letter to StockholdersSAN DIEGO, CA / ACCESS Newswire / May 11, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, released its 2026 annual meeting proxy materials today, which included a corporate update letter to its stockholders from James Rolke, Chief Executive Officer of Revelation, the body of the letter follows.Dear Stockholders:As you know, Revelation is a clinical stage company working to develop a high-impact, potentially lifesaving drug called Gemini for the treatment of acute kidney injury (AKI). While our passionate team is dedicated and hardworking, we couldn't a
- SECRevelation Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
- NEWSRevelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026SAN DIEGO, CA / ACCESS Newswire / May 7, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today reported its financial results for the three months ended March 31, 2026.Corporate HighlightsAnnounced agreement with FDA on a single adaptive Phase 2/3 study for approval of Gemini for treatment of acute kidney injuryReceived net proceeds of $6.7 million from warrant inducement in January 2026Participated in a fireside chat at the 38th Annual ROTH Conference, during which management discussed the Company's developments and strategic prioritiesPresented addit
- SECSEC Form 10-Q filed by Revelation Biosciences Inc.10-Q - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
- INSIDERChief Executive Officer Rolke James covered exercise/tax liability with 10,115 shares, decreasing direct ownership by 4% to 214,738 units (SEC Form 4) to cover withholding tax4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)
- INSIDERChief Financial Officer Zygmont Chester Stanley Iii covered exercise/tax liability with 13,285 shares (SEC Form 4) to satisfy withholding tax4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)
- SECSEC Form PRE 14A filed by Revelation Biosciences Inc.PRE 14A - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
- SECSEC Form S-8 filed by Revelation Biosciences Inc.S-8 - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
- NEWSRevelation Biosciences Announces Formation of Acute Kidney Injury Advisory BoardSAN DIEGO, CA / ACCESS Newswire / April 6, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today announced formation of an Acute Kidney Injury (AKI) Advisory Board for the upcoming Phase 2/3 AKI clinical trial. This distinguished panel brings together internationally recognized Nephrologists and Critical Care Physicians who will guide the company's clinical strategy, monitor progress, and ensure the initiative achieves the goal of improving patient care by advancing Gemini for the treatment of AKI. Their collective insight will help inform the most per
- NEWSRevelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical Study- A majority of CKD patients present with cellular inflammation and immunoparalysis predose --Gemini durably normalizes cellular inflammation and restores immunocompetence -SAN DIEGO, CA / ACCESS Newswire / March 30, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on innovative solutions for acute and chronic disease, presented additional positive data analysis from the PRIME Study at the International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026) in San Diego (March 29 - April 1, 2026). Presented datademonstrated the capability of Gemini to normalize the hyperinflammatory state and resto
- NEWSREMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth ConferenceSAN DIEGO, CA / ACCESS Newswire / March 24, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, today announced a reminder of its participation in a fireside chat on Tuesday, March 24, 2026, at 2:00 p.m. PT, as part of the 38th Annual Roth Conference, in Dana Point, CA.The fireside chat will be webcast live here and available on our Investors section of the Revelation Biosciences website, www.RevBiosciences.com, after the meeting.About Revelation Biosciences, Inc.Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on rebalancing inflammation
- SECRevelation Biosciences Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
- NEWSRevelation Biosciences to Host Fireside Chat at 38th Annual Roth ConferenceSAN DIEGO, CA / ACCESS Newswire / March 19, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, announced today that James Rolke, Revelation's Chief Executive Officer, and Chester S. Zygmont, III, Revelation's Chief Financial Officer, will be attending the 38th Annual Roth Conference, in Dana Point, CA, on Monday and Tuesday March 23rd and 24th. On Tuesday, March 24, 2026, at 2:00 p.m. PT, the Company will participate in a fireside chat.The fireside chat will be webcast live here and available on our Investors section of the Revelation Biosciences website, www.RevBios
- SECRevelation Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
- NEWSRevelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025SAN DIEGO, CA / ACCESS Newswire / February 26, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, today reported its financial results for the three and twelve months ended December 31, 2025.Corporate HighlightsAnnounced Positive Results from PRIME Clinical Study in late-stage chronic kidney disease patientsAnnounced agreement with FDA on a single adaptive Phase 2/3 study for approval of Gemini for treatment of acute kidney injuryReceived net proceeds of $6.7 million from warrant inducement in January 2026Clinical data on the potential therapeutic benefit of Gemini f
- SECSEC Form 10-K filed by Revelation Biosciences Inc.10-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Revelation Biosciences Inc.SCHEDULE 13G/A - REVELATION BIOSCIENCES, INC. (0001810560) (Subject)
- SECSEC Form DEF 14A filed by Revelation Biosciences Inc.DEF 14A - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
- SECSEC Form EFFECT filed by Revelation Biosciences Inc.EFFECT - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
- SECSEC Form 424B3 filed by Revelation Biosciences Inc.424B3 - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
- SECSEC Form PRE 14A filed by Revelation Biosciences Inc.PRE 14A - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)
REVB FAQ
7 questionsWhat does Revelation Biosciences Inc. do?
Revelation Biosciences, Inc., a clinical -stage biopharmaceutical company, focuses on the development or commercialization of innate immune system therapeutics and diagnostics. The company's lead therapeutic candidate is REVTx-99, an anti -viral nasal drop for the prevention or treatment of respiratory viral infections, as well as for the prevention or treatment of nasal congestion due to allergies or chronic rhinosinusitis. Its lead diagnostic is the REVDx -501, a rapid test kit to detect various respiratory viral infections. The company also develops REVTx-200, an intranasal immunomodulator...Where does REVB stock trade?
Revelation Biosciences Inc. (REVB) is listed on NASDAQ.What sector and industry is REVB in?
Revelation Biosciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Revelation Biosciences Inc. go public?
Revelation Biosciences Inc. (REVB) completed its IPO in 2020.What are analysts saying about REVB?
Revelation Biosciences Inc. has had 1 recent analyst action on file. The most recent action was from Roth Capital: Buy with a $1200.00 price target on 2022-02-17. Recent price targets cluster around $1200.00.What companies are similar to REVB?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare REVB side-by-side with any of them on Quantisnow.How can I track REVB on Quantisnow?
Quantisnow aggregates Revelation Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow REVB to receive live email and push alerts on every new disclosure.